Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,513.50 +465.90 (+0.74%) CMC Crypto 200
1,391.04 -5.50 (-0.39%)
Oncotelic Therapeutics, Inc. (OTLC)
| Previous close | 0.0408 |
| Open | 0.0400 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.0361 - 0.0420 |
| 52-week range | 0.0100 - 0.0500 |
| Volume | |
| Avg. volume | 74,853 |
| Market cap | 16.787M |
| Beta (5Y monthly) | 0.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings date | 18 May 2024 - 22 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireLinkage of Cancer and Lupus in Gliomas Patients
AGOURA HILLS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas: Past, Present, and Future Strategies in the Treatment and Management of Gliomas. Dr. Vuo
- GlobeNewswire
Invitation to Participate in STOP-PC Clinical Trial
AGOURA HILLS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) invites participation in our STOP-PC clinical trial which is now open for recruitment. Additional information can be obtained at www.stop-pc.com. An explainer video is available at https://www.youtube.com/watch?v=C4ZsE3fulIU. STOP-PC is a Randomized Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination with mFOLFIRINOX Compared with mFOLFIRINOX Alone in Patie
- GlobeNewswire
Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients
AGOURA HILLS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) and Interferon Gamma Receptor 2 (IFNGR2) mRNA Levels in the Brainstem Tumor Microenvironment (TME) Significantly Impact Overall Survival in Pediatric DMG Patients in the Special Issue Gliomas: Signaling Pathways, Molecular Mechanisms and Therapeutic Approaches. "In light of our foundational discovery that eleva
